Date: 2015-08-30
Type of information: Clinical research agreement
Compound: entinostat and atezolizumab
Company: Genentech, a member of Roche Group (USA - CA - Switzerland) Syndax Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: enzyme inhibitor/histone deacetylase inhibitor/monoclonal antibody/immune checkpoint inhibitor. Entinostat is a synthetic benzamide derivative that binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. Atezolizumab (MPDL3280A) is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1).
Disease: triple-negative breast cancer
Details: * On August 26, 2015, Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced that it has entered into a clinical collaboration with Genentech to evaluate the safety, tolerability and preliminary efficacy of Syndax\'s entinostat in combination with Genentech\'s atezolizumab (MPDL3280A), in patients with triple-negative breast cancer. Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells. Syndax will be responsible for conducting the Phase 1b/2 clinical trial in triple-negative breast cancer and the agreement includes a provision where the parties may extend the collaboration to include a Phase 3 clinical trial as well as additional trials in new indications of mutual interest.
Financial terms:
Latest news:
